283 related articles for article (PubMed ID: 16351663)
1. Pure red cell aplasia in a prostate cancer patient treated with leuprolide acetate and chlormadinone acetate.
Kobayashi M; Nukui A; Morita T
Int J Urol; 2005 Nov; 12(11):1010-1. PubMed ID: 16351663
[TBL] [Abstract][Full Text] [Related]
2. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer.
Yamanaka H; Ito K; Naito S; Tsukamoto T; Usami M; Fujimoto H; Matsuoka N; Fukui I; Harada M; Ohashi Y; Kotake T; Kakizoe T
Prostate; 2005 Apr; 63(1):56-64. PubMed ID: 15468166
[TBL] [Abstract][Full Text] [Related]
4. Leuprolide causes pure red cell aplasia.
Maeda H; Arai Y; Aoki Y; Okubo K; Okada T; Ueda Y
J Urol; 1998 Aug; 160(2):501. PubMed ID: 9679912
[No Abstract] [Full Text] [Related]
5. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
[TBL] [Abstract][Full Text] [Related]
6. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
Akaza H
BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
[TBL] [Abstract][Full Text] [Related]
7. [Total androgen blockade--concept, theory, method and clinical application].
Ozono S; Hirao Y
Nihon Rinsho; 1998 Aug; 56(8):2129-34. PubMed ID: 9750521
[TBL] [Abstract][Full Text] [Related]
8. [Diphenylhydantoin-induced pure red cell aplasia after neurological surgery: report of two cases].
Tanaka S; Toujou H; Tara M; Uetsuhara K
No Shinkei Geka; 2000 Aug; 28(8):713-7. PubMed ID: 11002494
[TBL] [Abstract][Full Text] [Related]
9. Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer.
Curtis KK; Pruthi RK; Fonseca R; Gornet MK
Urology; 2007 Oct; 70(4):811.e5-8. PubMed ID: 17991572
[TBL] [Abstract][Full Text] [Related]
10. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
Daskivich TJ; Oh WK
Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
[TBL] [Abstract][Full Text] [Related]
11. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
[TBL] [Abstract][Full Text] [Related]
12. [Clinical study on chlormadinone acetate alone followed by combination with LH-RH analogue for prostatic cancer: effects on lipid metabolism].
Shimada M; Uchida H; Kasahara T; Fuji K; Ogawa Y; Yoshida H; Hamajima T; Matsuda N; Ikeuchi T; Kai Y; Hiramori M; Hoshino M; Inoue K; Higaki Y
Hinyokika Kiyo; 1998 Jul; 44(7):525-32. PubMed ID: 9752613
[TBL] [Abstract][Full Text] [Related]
13. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
Curry EA; Sweeney CJ
J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
[No Abstract] [Full Text] [Related]
14. Watchful waiting beats androgen deprivation therapy in early prostate cancer.
Brower V
J Natl Cancer Inst; 2008 Nov; 100(21):1494-6. PubMed ID: 18957680
[No Abstract] [Full Text] [Related]
15. Granulomas induced by subcutaneous injection of leuprorelin acetate.
Sakamoto R; Higashi Y; Mera K; Kanekura T; Kanzaki T
J Dermatol; 2006 Jan; 33(1):43-5. PubMed ID: 16469084
[TBL] [Abstract][Full Text] [Related]
16. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
17. Localized amyloidosis of the seminal vesicle. Possible association with hormonally treated prostatic adenocarcinoma.
Unger PD; Wang Q; Gordon RE; Stock R; Stone N
Arch Pathol Lab Med; 1997 Dec; 121(12):1265-8. PubMed ID: 9431316
[TBL] [Abstract][Full Text] [Related]
18. Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group.
Akaza H; Homma Y; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Ohashi Y; Aso Y
Jpn J Clin Oncol; 2000 Mar; 30(3):131-6. PubMed ID: 10798540
[TBL] [Abstract][Full Text] [Related]
19. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
20. Anaphylaxis to leuprolide acetate depot injection during treatment for prostate cancer.
Grant JP; Levinson AW
Clin Genitourin Cancer; 2007 Mar; 5(4):284-6. PubMed ID: 17553209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
